BridgeBio Pharma Shares Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-Dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma, Inc. (NASDAQ:BBIO) has shared new long-term data from its Phase 2 trial in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The data remains consistent with earlier results, showing a well-tolerated safety profile and encouraging preliminary efficacy. Early changes in glycosylated ⍺DG levels at 3 months appear to be associated with ambulatory improvements at 9 months, supporting the potential use of glycosylated ⍺DG levels as a surrogate endpoint in the ongoing Phase 3 study for accelerated approval.
October 09, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma's new long-term data from its Phase 2 trial shows promising results, which could potentially accelerate the approval of its ongoing Phase 3 study.
The positive long-term data from BridgeBio Pharma's Phase 2 trial is a significant development for the company. The data shows a well-tolerated safety profile and encouraging preliminary efficacy, which could potentially accelerate the approval of its ongoing Phase 3 study. This development is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100